<![CDATA[Background: Pulmonary tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, which is transmitted via droplets inhaled by individuals near active TB patients. Meanwhile, diabetes mellitus (DM)is an independent risk factor for TB infection and can increase the risk of latent TB reactivation due to a weakened immune system. The coexistence of TB and DM can impair the absorption of first-line anti-tuberculosis drugs (ATD), making patients more vulnerable to treatment failure, relapse, and increased mortality. Therefore, this study aims to assess the association between glycemic control status and treatment outcomes of first-line ATD therapy. Method: This study used an analytical observational, cross-sectional design and included 86 medical records of pulmonary TB patients with DM, selected through simple random sampling. Bivariate analysis was conducted using the Chi-square test or Fisher’s exact test, with P<0.05 considered statistically significant. Results: Most patients were adults aged 18–59 years (66.3%) and male (55.8%), with the majority having uncontrolled blood glucose levels (75.6%) and normal nutritional status (38.4%). The most common treatment duration was nine months (76.7%). All patients showed clinical improvement and sputum conversion (100%), while 81.4% showed radiological improvement. Bivariate analysis showed a significant difference in radiological improvement between patients with controlled and uncontrolled DM (P=0.009). Conclusion: The majority of pulmonary TB patients with DM were aged 18–59 years, male, and had uncontrolled blood glucose levels. All patients showed clinical improvement and sputum conversion, while 81.4% experienced radiological improvement, with a significant difference between controlled and uncontrolled DM.]]>
